Janux Therapeutics Hosts Virtual Event to Present Initial JANX011 Phase 1 Data

• Janux Therapeutics will host a virtual event on Nov. 9, 2026, at 8:30 a.m. ET.
• CEO David Campbell will present initial Phase 1 single-ascending-dose study data for JANX011 in healthy volunteers.
• The presentation will review safety, pharmacokinetics and pharmacodynamics, including implications for JANX011’s autoimmune disease development and the broader ARM platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611021602BIZWIRE_USPR_____20261102_BW405202) on November 02, 2026, and is solely responsible for the information contained therein.